Communiqués PAVmed Inc.

Actions

PAVM

US70387R4039

Temps réel estimé Cboe BZX Autres places de cotation 16:36:42 02/07/2024			Varia. 5j.	Varia. 1 janv.
0,739 ^USD	-3,27%		+1,21%	-81,80%

13:55	Lucid Diagnostics annonce les résultats positifs de l'étude prospective internationale multicentrique ESOGUARD BE-1 sur la validation clinique du test Esoguard® pour le dépistage des lésions précancéreuses de l'œsophage dans une population de dépistage.	CI
20/06	Transcript : PAVmed Inc. - Shareholder/Analyst Call

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

4,000th Firefighter Undergoes Lucid Diagnostics EsoGuard Esophageal Precancer Testing	13/06	AQ
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	13/06	PR
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall	09/05	PR
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors	07/05	PR
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024	06/05	AQ
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024	03/05	PR
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024	02/05	PR
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	30/04	PR
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month	29/04	PR
PAVmed : Material Agreement - Form 8-K	26/04	PU
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	08/04	PR
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21/03	PR
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference	20/03	PR
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024	13/03	PR
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024	12/03	PR
PAVmed : Failure to Satisfy Listing Rule - Form 8-K	08/03	PU
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	19/02	AQ
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program	16/02	PR
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony	15/02	PR
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors	09/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués PAVmed Inc.

Actions

PAVM

US70387R4039

Communiqués

Filtres